Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Kazia Therapeutics Limited - American Depositary Shares
(NQ:
KZIA
)
5.345
-0.015 (-0.28%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jun 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kazia Therapeutics Limited - American Depositary Shares
< Previous
1
2
3
4
5
Next >
Kazia Therapeutics' Shares Gain Following FDA Orphan Drug Status For Childhood Brain Cancer Drug
June 17, 2022
The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ: KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 17, 2022
Via
Benzinga
Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
May 26, 2022
LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address...
From
Edison Investment Research Limited
Via
AccessWire
Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer
April 21, 2022
Kazia Therapeutics Limited (NASDAQ: KZIA) has completed a Phase 2 study of paxalisib in glioblastoma.
Via
Benzinga
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
April 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
March 30, 2022
LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential...
From
Edison Investment Research Limited
Via
AccessWire
A Peek Into The Markets: US Stock Futures Gain After S&P 500 Hits Record High
December 13, 2021
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones surged more than 200 points in the previous session. Investors are awaiting earnings...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
60 Biggest Movers From Yesterday
December 07, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore...
Via
Benzinga
Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients
December 03, 2021
Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced final data from a Phase 2 study of paxalisib as first-line therapy in patients with...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings
November 15, 2021
Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are awaiting earnings results from Tyson Foods,...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:
Via
Benzinga
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
October 14, 2021
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly...
From
Edison Investment Research Limited
Via
AccessWire
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
April 20, 2021
LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for...
From
Edison Investment Research Limited
Via
AccessWire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 14, 2021
Gainers Akumin (NASDAQ:AKU) shares increased by 13.54% to $3.52 during Wednesday's pre-market session. The market value of their outstanding shares is at $247.0...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.